A retrospective study of SBRT of metastases in patients with primary sarcoma

Abstract

We retrospectively reviewed the results of stereotactic body radiotherapy (SBRT) in 46 patients with a total of 136 metastases from primary sarcoma. The purpose of this study was to evaluate the overall response rate and side effects of SBRT in metastatic sarcoma. The patients were treated at Karolinska University Hospital between 1994 and 2005, using 3D conformal multifield technique and a stereotactic body-frame. Prescribed doses ranged from 4 to 20 Gy per fraction in 1–5 fractions, with total doses of 10–48 Gy. All 46 patients were diagnosed with a primary sarcoma. The treated metastases were localized mainly in the lungs. A total number of 136 metastases were treated (1–14 per patient). Overall response rate (local control = CR, PR and SD) for each tumour was 88 % (119/135). Median follow-up was 21.8 months (range 2.7–112.8 months). Thirteen patients (31 %) were long-term survivors (>36 months), and 5 patients are still alive after last follow-up. Two cases of serious non-lethal side effects were seen, one patient had a colon perforation and another patient had contracture of the hip region. SBRT is a safe, convenient and effective non-invasive treatment with high local control for patients with metastatic sarcoma.Electronic supplementary materialThe online version of this article (doi:10.1007/s12032-012-0256-2) contains supplementary material, which is available to authorized users.

Single-institution Experience of SBRT for Lung Metastases in Sarcoma Patients

“…Those authors concluded that SBRT is an effective and safe treatment for patients with metastatic sarcoma. 6 Dhakal and colleagues described 15 patients treated by SBRT for metastatic soft-tissue sarcoma to the lung. Seventy-four lesions were treated with 50 Gy in 5 fractions.…”

Effect on Survival of Local Ablative Treatment of Metastases from Sarcomas: A Study of the French Sarcoma Group

“…About 50% of patients with sarcoma will experience metastases during the course of the disease. The median overall survival for metastatic sarcomas went from 12 months in the 1990s [5] to 18e24 months in recent studies [6,7]. Local treatments have increasingly been used in recent years for cases of sarcoma.…”

Definitive radiotherapy in the management of non-resectable or residual retroperitoneal sarcomas: institutional cohort analysis and systematic review

“…Literature data suggests various, but often low alpha/beta ratio of sarcomas, mostly between 0.4 and 5 Gy [16]. Thus, we assumed alpha/beta ratio of sarcomas as 3 to calculate EQD2 [17].…”